BioChem Analysis


BioChem Analysis is focused on the development and increased application of stable non-radioactive isotopes to biomedical research.

BioChem Analysis is focused on the development and increased application of stable non-radioactive isotopes to biomedical research.

Company (Alive / Active)

Phone:

Fax:

2201 West Campbell Park Dr Ste 28
Chicago, 60612
Illinois, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
BioChem Analysis $0M Nov 30, 2018
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related BioChem Analysis Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Lifenova Biomedical SA

Spain
Alive / ActiveLIFENOVA Biomedical, S.A. was set up as a partnership between the medical & engineering community. Extensive research is being carried out in different biomedical applications, where surface properties play a key role. Among then, it can already be highlighted the results obtained on dental implants, which have already led to a implant surface with outstanding and solidly tested osseointegration characteristics.nLogin to see details

Cellerant Therapeutics

San Carlos, California, United States
Alive / ActiveCellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia,...Show allLogin to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)